A treatment that blocks the action of ghrelina peptide that has been called a "hunger hormone" -- leads to weight loss and other beneficial metabolic effects in mice, according to new research.
Brad Barnett and colleagues have designed a drug that interferes with this particular peptide hormone, known to promote weight gain in mammals through a variety of mechanisms, including the stimulation of appetite.
They knew that ghrelin is not active unless it carries a specific octanoyl side chain, which is added by an enzyme called ghrelin O-acyltransferase, or GOAT.
So, Barnett and his team designed a peptide-based drug called GO-CoA-Tat, which inhibits GOAT, and they injected it into mice that were being fed high-fat diets.
They observed that the drug improved glucose tolerance and slowed weight gain in the mice, but interestingly, it did not appear to reduce food intake, a finding that suggests the drug affects metabolism rather than appetite.
GO-CoA-Tat requires repeated injections and is therefore unlikely to be developed into a drug for human obesity, but this study does establish GOAT as a potentially valuable target for future drug development efforts.
Explore further: Erectile dysfunction drugs could protect liver from sepsis-induced damage
More information: "Glucose and Weight Control in Mice with a Designed Ghrelin O-Acyltransferase Inhibitor," by B.P. Barnett et al. Science: DOI:10.1126/science.1196154